Page 22 - LG Cancro endometrio

Queste Linee Guida sono stae elaborate dalla ESMO, ESGO e dalla
ESTRO, e pubblicate in collaborazione su Annals of Oncology,
l’International Journal of Gynecological Cancer and Radiotherapy
& Oncology. Le tre società hanno nominato i loro rappresenti
che hanno partecipato alla consensus conference.

Membri partecipatni alla ESMO-ESGO-ESTRO Consensus Conference sul carcinoma

dell’endometrio. Gruppo di lavoro:

M. Abal, Translational Medical Oncology (IDIS), Complexo Hospitalario Universitario de Santiago
de Compostela (SERGAS), Santiago de Compostela, Spain; O. Altundag, Department of Medical
Oncology, BaÅŸkent University Hospital, Ankara, Turkey; F. Amant, Department of Gynecological
Oncology, University Hospital Leuven, Leuven, Belgium and Center for Gynecological Oncology
Amsterdam (CGOA), Antoni van Leeuwenhoek, Amsterdam, The Netherlands; S. Banerjee,
Gynaecology Unit, The Royal Marsden NHS Foundation Trust, London, UK; T. Bosse, Department
of Pathology, Leiden University Medical Center, Leiden, The Netherlands; A. Casado, EORTC
Gynecological tumor group, Hospital Universitario San Carlos, Madrid, Spain; L. C. de Agustín, MD
Anderson Cancer Center, Madrid, Spain and University of Texas, USA; D. Cibula, Department of
Obstetrics and Gynecology, Charles University, Prague, Czech Republic; N. Colombo, Division of
Medical Gynecologic Oncology, European Institute of Oncology and University of Milan- Bicocca,
Milan, Italy; C. Creutzberg, Department of Radiation Oncology, Leiden University Medical Center,
Leiden, The Netherlands; J.-M. del Campo, Division of Medical Oncology, Vall d’Hebron Institute of
Oncology, Barcelona, Spain; G. Emons, Department of Obstetrics & Gynecology, Georg- August-
Universität Göttingen, Frauenklinik, Göttingen, Germany; F. Goffin, Department of Gynecologic
Oncology, CHU Liège, Site Hôpital de la Citadelle, Liège, Belgium; A. González- Martín,
Department of Medical Oncology, GEICO and MD Anderson Cancer Center, Madrid, Spain;
S. Greggi, Department of Gynecologic Oncology, National Cancer Institute of Naples, Naples,
Italy; C. Haie-Meder, Department of Radiation Oncology, Brachytherapy Service, Gustave Roussy
Hospital, Villejuif, France; D. Katsaros, Department of Gynecologic Oncology, Azienda Ospedaliero-
Universitaria Città della Salute, Sant’Anna Hospital and University of Turin, Turin, Italy; V. Kesic,
Medical Faculty, University of Belgrade and Department of Obstetrics and Gynecology, Clinical
Center of Serbia, Belgrade, Serbia; C. Kurzeder, Department of Gynaecology and Gynaecologic
Oncology, Kliniken Essen-Mitte, Essen, Germany; S. Lax, Department of Pathology, Hospital Graz
West, Graz, Austria; F. Lécuru, Service de Chirurgie Gynécologique et Cancérologique, Hôpital
Européen Georges Pompidou, Paris, France; J. Ledermann, Department of Oncology and Cancer
Trials, UCL Cancer Institute, London, UK; T. Levy, Division of Gynecologic Oncology, Wolfson
Medical Center, Tel-Aviv University, Holon, Israel; D. Lorusso, Department of Gynecologic Oncology,
Fondazione ‘IRCCS’ National Cancer Institute of Milan, Milan, Italy; J. Mäenpää, Department of
Obstetrics and Gynecology, University of Tampere and Tampere University Hospital, Tampere,
Finland; C. Marth, Department of Obstetrics and Gynecology, Innsbruck Medical University,
Innsbruck, Austria; X. Matias-Guiu, Department of Pathology and Molecular Genetics and Research
Laboratory, Hospital Universitari Arnau de Vilanova, University of Lleida, Lleida, Spain; P. Morice,
Department of Gynaecological Surgery, Institut Gustave Roussy, Villejuif, France; H. W. Nijman,
Department of Gynaecologic Oncology, University Medical Center Groningen, University of
Groningen, Groningen, The Netherlands; R. Nout, Department of Radiotherapy, Leiden University
Medical Center, Leiden, The Netherlands; M. Powell, Department of Clinical Oncology, Barts Health
NHS Trust, St Bartholomew’s Hospital, West Smithfield, London, UK; D. Querleu, Department of
Surgery, Institut Bergonié, Bordeaux, France and Department of Gynecology and Obstetrics, McGill
University Health Centre, Montreal, Quebec, Canada; M. R. Mirza, Department of Oncology,

22 Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark; N. Reed, Department